Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
REGULATORY
Japan Mulls Full Overhaul of LLP Rule under FY2026 Drug Pricing Reform
Japan’s Ministry of Health, Labor and Welfare (MHLW) proposed a full review of the so-called “G1/G2” rule — a framework that phases down the prices of long-listed products (LLPs) towards generic levels — at a meeting of its key drug…
To read the full story
Related Article
- G1 Rule to Hit Originator Biologics for First Time, Impact Seen for Up to 13 Brands
February 25, 2026
- MHLW Proposes Pricing New AGs and Bio-AGs on Par with Originators
December 4, 2025
- Japan Moves to Advance “G1” Price Cuts by 5 Years under Proposed LLP Overhaul
November 20, 2025
- Exclude High-Price-Gap Products from Unprofitable Drug Re-Pricing: Chuikyo
October 30, 2025
- Japan Eyes Review of Generic Price Bands, Brand-Based Revisions for Tier A Products
October 30, 2025
REGULATORY
- AMED Warns Projects without Japan Return May Miss Startup Funding
March 26, 2026
- Japan Cabinet Approves National MCM Strategy to Boost Pandemic Response
March 25, 2026
- Pharma Urges Govt Support as Iran War Shows Early Impact on Supply Chains
March 25, 2026
- Japan Panel Slams MHLW’s 80% Single-IRB Target as Too Low
March 24, 2026
- Ishin Proposes Macroeconomic Indexing for Healthcare as LDP Talks Resume
March 24, 2026
Japan’s FY2026 drug price revision, officially announced on March 5, has landed poorly with the pharmaceutical industry — and the…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…